ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 22 filers reported holding ASCENDIS PHARMA A/S in Q3 2016. The put-call ratio across all filers is - and the average weighting 1.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $1,100,000 | +166.3% | 8,175 | +205.5% | 0.14% | +100.0% |
| Q3 2020 | $413,000 | +36.8% | 2,676 | +23.1% | 0.07% | +97.1% |
| Q4 2019 | $302,000 | +73.6% | 2,174 | -83.4% | 0.04% | +250.0% |
| Q2 2016 | $174,000 | -49.9% | 13,100 | -29.9% | 0.01% | -54.5% |
| Q1 2016 | $347,000 | – | 18,700 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |